Clostridium difficile infection in fever patients with gynecological malignancies.
Clostridium difficile infection
chemoradiotherapy
chemotherapy
diarrhea
fever
gynecology
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
18
12
2018
revised:
15
04
2019
accepted:
16
04
2019
entrez:
29
7
2020
pubmed:
29
7
2020
medline:
5
10
2021
Statut:
ppublish
Résumé
Although Clostridium difficile infection (CDI) often results in severe manifestations due to toxin-producing clostridium, the correlation between CDI and having a fever in gynecological malignancies is not completely understood. The incidence, and clinical features, and clinical management of CDI in patients with gynecological malignancies who have fevers were investigated, and the clinical managements of this complication are discussed. We retrospectively reviewed 485 patients newly diagnosed with invasive gynecological cancers who underwent anticancer treatment between July 2012 and December 2016. The diagnosis of CDI was performed using enzyme immunoassays for C difficile glutamate dehydrogenase and toxin A/B enzyme immunoassay. The cumulative risk of CDI was 9.5% (six of 63) in overall fever patients and 6.3% (six of 95) in patients with fever episodes. Two CDI patients (33.3%) did not show diarrheal symptoms, with the fever of unknown origin criteria prompting their CDI testing and diagnosis. CDI patients were treated using vancomycin or metronidazole without suffering from fatal clinical course. Overall, eight patients with gynecological malignancies were diagnosed with CDI, including two patients with fever lower than 38.5°C. The cumulative risk of CDI was 0.48% (eight of 1652) for all admitted patients and 1.6% (eight of 485) in those with gynecological malignancies. Of all the patients with confirmed CDI, only one had a history of administration of antibiotics prior to onset of CDI symptoms. CDI does not always present with typical manifestations in malignancy patients. Investigation of CDI, regardless of gastrointestinal symptoms or history of antibiotic use, is warranted in cases of fever of unknown origin in gynecological malignancy.
Sections du résumé
BACKGROUND
Although Clostridium difficile infection (CDI) often results in severe manifestations due to toxin-producing clostridium, the correlation between CDI and having a fever in gynecological malignancies is not completely understood.
AIMS
The incidence, and clinical features, and clinical management of CDI in patients with gynecological malignancies who have fevers were investigated, and the clinical managements of this complication are discussed.
METHODS AND RESULTS
We retrospectively reviewed 485 patients newly diagnosed with invasive gynecological cancers who underwent anticancer treatment between July 2012 and December 2016. The diagnosis of CDI was performed using enzyme immunoassays for C difficile glutamate dehydrogenase and toxin A/B enzyme immunoassay. The cumulative risk of CDI was 9.5% (six of 63) in overall fever patients and 6.3% (six of 95) in patients with fever episodes. Two CDI patients (33.3%) did not show diarrheal symptoms, with the fever of unknown origin criteria prompting their CDI testing and diagnosis. CDI patients were treated using vancomycin or metronidazole without suffering from fatal clinical course. Overall, eight patients with gynecological malignancies were diagnosed with CDI, including two patients with fever lower than 38.5°C. The cumulative risk of CDI was 0.48% (eight of 1652) for all admitted patients and 1.6% (eight of 485) in those with gynecological malignancies. Of all the patients with confirmed CDI, only one had a history of administration of antibiotics prior to onset of CDI symptoms.
CONCLUSION
CDI does not always present with typical manifestations in malignancy patients. Investigation of CDI, regardless of gastrointestinal symptoms or history of antibiotic use, is warranted in cases of fever of unknown origin in gynecological malignancy.
Identifiants
pubmed: 32721136
doi: 10.1002/cnr2.1200
pmc: PMC7941536
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1200Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
J Hosp Infect. 1994 May;27(1):1-15
pubmed: 7916358
Clin Infect Dis. 2002 Jun 15;34(12):1585-92
pubmed: 12032893
Gynecol Oncol. 1996 Jun;61(3):369-72
pubmed: 8641617
South Med J. 1997 Sep;90(9):889-92
pubmed: 9305296
Am J Med. 2003 Nov;115(7):543-6
pubmed: 14599633
Gynecol Oncol. 1998 Oct;71(1):104-7
pubmed: 9784328
Jpn J Infect Dis. 2012 Jul;65(4):326-9
pubmed: 22814157
Obstet Gynecol. 1989 Sep;74(3 Pt 2):487-9
pubmed: 2761938
Anticancer Res. 2005 May-Jun;25(3c):2509-13
pubmed: 16080485
Am J Gastroenterol. 2000 Nov;95(11):3137-41
pubmed: 11095331
Arch Intern Med. 1992 Aug;152(8):1715-7
pubmed: 1497405
Can Fam Physician. 2004 Nov;50:1536-40, 1543-5
pubmed: 15597970
J Hosp Infect. 1998 Feb;38(2):101-12
pubmed: 9522288
Cancer Rep (Hoboken). 2019 Oct;2(5):e1200
pubmed: 32721136
N Engl J Med. 1978 Mar 9;298(10):531-4
pubmed: 625309
Postgrad Med J. 2005 Jun;81(956):367-9
pubmed: 15937201
J Infect Chemother. 2011 Jul;17 Suppl 1:137-9
pubmed: 21728113
Ann Intern Med. 1989 Feb 15;110(4):255-7
pubmed: 2643913
Curr Med Chem. 2016;23(39):4442-4449
pubmed: 27804875
Ann Intern Med. 2017 Aug 1;167(3):152-158
pubmed: 28672282
J Med Microbiol. 1987 May;23(3):211-9
pubmed: 3585958
Br J Cancer. 1986 Mar;53(3):355-60
pubmed: 3516192
Arch Intern Med. 2001 Feb 26;161(4):525-33
pubmed: 11252111
Lancet. 1978 May 20;1(8073):1063-6
pubmed: 77366
Gynecol Oncol. 2006 Oct;103(1):181-5
pubmed: 16574203